223 related articles for article (PubMed ID: 35771588)
1. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
2. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
3. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
4. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
5. A novel screening method to assess developability of antibody-like molecules.
Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA
MAbs; 2015; 7(4):752-8. PubMed ID: 25961854
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
7. Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.
Gupta P; Horspool AM; Trivedi G; Moretti G; Datar A; Huang ZF; Chiecko J; Kenny CH; Marlow MS
J Biol Chem; 2024 Jan; 300(1):105555. PubMed ID: 38072062
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
[TBL] [Abstract][Full Text] [Related]
9. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning.
Makowski EK; Chen H; Lambert M; Bennett EM; Eschmann NS; Zhang Y; Zupancic JM; Desai AA; Smith MD; Lou W; Fernando A; Tully T; Gallo CJ; Lin L; Tessier PM
MAbs; 2022; 14(1):2146629. PubMed ID: 36433737
[TBL] [Abstract][Full Text] [Related]
10. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
11. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
13. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice.
Kelly RL; Sun T; Jain T; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Vásquez M; Wittrup KD; Xu Y
MAbs; 2015; 7(4):770-7. PubMed ID: 26047159
[TBL] [Abstract][Full Text] [Related]
14. Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies.
Zhou M; Yan Z; Li H; Liu X; Sun P
Pharm Res; 2021 Apr; 38(4):721-732. PubMed ID: 33754257
[TBL] [Abstract][Full Text] [Related]
15. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
[TBL] [Abstract][Full Text] [Related]
16. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
Park E; Izadi S
MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
[No Abstract] [Full Text] [Related]
17. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
18. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.
Estep P; Caffry I; Yu Y; Sun T; Cao Y; Lynaugh H; Jain T; Vásquez M; Tessier PM; Xu Y
MAbs; 2015; 7(3):553-61. PubMed ID: 25790175
[TBL] [Abstract][Full Text] [Related]
19. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
[TBL] [Abstract][Full Text] [Related]
20. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
